TY - CHAP M1 - Book, Section TI - Immune Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy A1 - Maciocia, Paul M. A1 - Maciocia, Nicola C. A1 - Pule, Martin A. A2 - Kaushansky, Kenneth A2 - Prchal, Josef T. A2 - Burns, Linda J. A2 - Lichtman, Marshall A. A2 - Levi, Marcel A2 - Linch, David C. PY - 2021 T2 - Williams Hematology, 10e AB - SUMMARYAdoptive cellular therapy, in which immune cells are selected or engineered to direct specificity toward diseased cells, has recently proved efficacious in some cancers, particularly including several of the hematologic malignancies. These therapies include tumor-infiltrating lymphocytes, T-cell receptor transgenic cells, and chimeric antigen receptor (CAR) T cells, with the latter being the most advanced for the treatment of hematologic malignancies. To produce CAR T cells, T lymphocytes are engineered to express synthetic immune signaling molecules, which fuse the specificity of an anti-tumor monoclonal antibody with the potent cytotoxic and immunosurveillance functions of T cells. In clinical studies, CAR T cells have engendered deep and long-lasting remissions in children and young adults with resistant and relapsed acute lymphoblastic leukemia and in adults with diffuse large B-cell lymphoma, with further promising data in myeloma. Although CAR T-cell therapy has the potential to transform cancer treatment as part of the “personalized medicine” revolution, important obstacles remain to be overcome. These include identification of further tumor-specific targets, enhancement of efficacy while reducing toxicity and cost, and increasing patient access. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1180477942 ER -